» Articles » PMID: 37249723

Low-Pass Genomic Sequencing Reveals Novel Subtypes of Pancreatic Cystic Neoplasms

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2023 May 30
PMID 37249723
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Over the years, the detection rate of pancreatic cystic neoplasms (PCNs) has significantly increased; however, the differential diagnosis and identification of high-risk PCNs remain challenging. We sought to investigate whether chromosomal instability (CIN) features in cell-free DNA in the cystic fluid of PCNs could help to identify high-risk PCNs.

Methods: Pancreatic cystic fluid samples from 102 patients with PCNs were intraoperatively collected for detection of CIN using an ultrasensitive chromosomal aneuploidy detector. Clinical and imaging data were retrospectively collected, and statistical analysis was performed to assess the potential role of CIN in clinical practice.

Results: CIN was investigated in a total of 100 patients. Sixteen of 26 serous cystic cystadenomas (SCAs) harbored deletions of chr3p and/or chr6p, whereas low rates of CIN were detected in mucinous cystic neoplasms. Most malignant PCNs presented with more than one type of CIN; amplification of chr1q and chr8q found in nine and seven of 11 malignant PCNs (81.8% and 63.6%), respectively, could aid in distinguishing high-risk IPMNs from low-risk ones, with a higher sensitivity than imaging. A combination of the mural nodule imaging feature and amplification of chr1q and chr8q achieved a sensitivity of 70.0% and a specificity of 82.4% in identifying high-risk IPMNs.

Conclusions: Our work revealed the distinct CIN signature of different types of PCNs. Deletions of chr3p and chr6p defined a subtype of SCAs. Gains of chr1q and chr8q were associated with insidious malignant PCNs and helped identify high-risk IPMNs.

Citing Articles

Prospects in the application of ultrasensitive chromosomal aneuploidy detection in precancerous lesions of gastric cancer.

Qian S, Xie F, Zhao H, Liu Q, Cai D World J Gastrointest Surg. 2024; 16(1):6-12.

PMID: 38328310 PMC: 10845279. DOI: 10.4240/wjgs.v16.i1.6.

References
1.
van Huijgevoort N, Del Chiaro M, Wolfgang C, van Hooft J, Besselink M . Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines. Nat Rev Gastroenterol Hepatol. 2019; 16(11):676-689. DOI: 10.1038/s41575-019-0195-x. View

2.
Stark A, Donahue T, Reber H, Hines O . Pancreatic Cyst Disease: A Review. JAMA. 2016; 315(17):1882-93. DOI: 10.1001/jama.2016.4690. View

3.
Roldan J, Harrison J, Qadan M, Bolm L, Baba T, Brugge W . "Evolving Trends in Pancreatic Cystic Tumors: A 3-Decade Single-Center Experience With 1290 Resections". Ann Surg. 2021; 277(3):491-497. DOI: 10.1097/SLA.0000000000005142. View

4.
Chen Y, Guo C, Zhang Q, Shen Y, Li Y, Li X . Patients with pancreatic cystic neoplasms can benefit from management of multidisciplinary team: Experience from a Chinese academic center. Pancreatology. 2018; 18(7):799-804. DOI: 10.1016/j.pan.2018.07.010. View

5.
Carr R, Yip-Schneider M, Simpson R, Dolejs S, Schneider J, Wu H . Pancreatic cyst fluid glucose: rapid, inexpensive, and accurate diagnosis of mucinous pancreatic cysts. Surgery. 2017; 163(3):600-605. DOI: 10.1016/j.surg.2017.09.051. View